Targeting interleukin 4 and interleukin 13: a novel therapeutic approach in bullous pemphigoid

Targeting interleukin 4 and interleukin 13: a novel therapeutic approach in bullous pemphigoid

AbstractAim: Bullous pemphigoid (BP) is an organ-specific autoimmune bullous disease characterized by autoantibodies that target the cellular adhesion molecules BP180 and BP230. Both immunoglobulin (Ig)G and IgE are involved in the induction of subepidermal blisters. Specifically, IgE autoantibodies...

Full description

Bibliographic Details
Main Authors: Fangyuan Chen, Yiman Wang, Xinyi Chen, Nan Yang, Li Li
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Annals of Medicine
Subjects:
Bullous pemphigoid
Th2 cells
interleukin-4
interleukin-13
dupilumab
monoclonal antibody therapy
Online Access:https://www.tandfonline.com/doi/10.1080/07853890.2023.2188487

Internet

https://www.tandfonline.com/doi/10.1080/07853890.2023.2188487

Similar Items